A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Overview of attention for article published in Journal of Neurodevelopmental Disorders, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

blogs: 1 blog

twitter: 6 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 83 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 85,523 followers.

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome https://t.co/5e2d5E2cnH

22 Mar 2022

Reply Repost Favourite

RT @autismcrisis: Basmisanil (vs placebo) "did not improve cognition or functioning in adults and adolescents with Down syndrome" https://t…

21 Feb 2022

Reply Repost Favourite

RT @Biotrial: Biotrial is very proud to have participated in this clinical program alongside @Roche . The experience gathered together on t…

10 Feb 2022

Reply Repost Favourite

Biotrial is very proud to have participated in this clinical program alongside @Roche . The experience gathered together on this trial has proven to be instrumental in supporting EEG research in several patient populations, in addition to Down syndrome. ht

10 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.